Redhill Biopharma
RDHL
24 hedge funds and large institutions have $20.1M invested in Redhill Biopharma in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
9% more funds holding
Funds holding: 22 → 24 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
19% less capital invested
Capital invested by funds: $24.9M → $20.1M (-$4.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$370K |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$360K |
| 3 |
Jane Street
New York
|
+$290K |
| 4 |
FM
Family Management
New York
|
+$170K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$2.63M |
| 2 |
NC
Nexthera Capital
New York
|
-$994K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$839K |
| 4 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$140K |
| 5 |
Morgan Stanley
New York
|
-$59.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWA
26
TCI Wealth Advisors
Tucson,
Arizona
| $3K | – | – | – |
|
|
27
Morgan Stanley
New York
| $2K | -$59.9K | -6 | Closed |
|
|
BC
28
Broadfin Capital
New York
| – | -$2.63M | -252 | Closed |
|
|
NC
29
Nexthera Capital
New York
| – | -$994K | -95 | Closed |
|
RDHL Hedge Fund Activity: Q1 2017 in Review
24 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2017, worth a combined $20.1M — down 19% from $24.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new RDHL positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $370K. The largest seller was Broadfin Capital, exiting entirely with an estimated $2.63M sold.
- 24 institutional investors held Redhill Biopharma (RDHL) as of Q1 2017, up from 22 in Q4 2016.
- Funds reported $20.1M of Redhill Biopharma stock for Q1 2017, down 19% quarter-over-quarter.
- 5 funds opened new Redhill Biopharma positions in Q1 2017 and 3 closed out, a net change of +2 holders.
- The largest Redhill Biopharma buyer in Q1 2017 was Renaissance Technologies, an estimated $370K added.
- The largest Redhill Biopharma seller in Q1 2017 was Broadfin Capital, an estimated $2.63M sold.
Based on aggregated 13F filings for Q1 2017.